TABLE 2.

Dosing and eGFR Prescribing Criteria for SGLT2 Inhibitors

Agent	FDA Approval	Starting Dose, mg*	Maximum Dose, mg*	eGFR Prescribing Criteria†
Canagliflozin	2013	100	300	Dose can be increased to 300 mg in patients tolerating 100 mg for those with an eGFR ≥60 who require additional glycemic control. Not recommended for use to improve glycemic control in adults with type 2 diabetes with an eGFR <30. Contraindicated in patients requiring dialysis.
Dapagliflozin	2014	5	10	Not recommended for glycemic control when eGFR is <45. Contraindicated in severe renal impairment; defined as eGFR <30 in patients who are being treated for glycemic control without established CVD or cardiovascular risk factors. Contraindicated in patients on dialysis.
Empagliflozin	2014	10	25	Do not initiate if eGFR is <45. Discontinue if eGFR falls to persistently <45. Contraindicated in severe renal impairment, ESRD, and dialysis.
Ertugliflozin	2017	5	15	Initiation is not recommended in patients with an eGFR <60. Continued use is not recommended in patients with eGFR of 30 to <60. Do not use in patients with an eGFR <30. Contraindicated in severe renal impairment, ESRD, and dialysis.

^*All doses are by mouth once daily.

^†All eGFR values are mL/min/1.73 m². FDA, U.S. Food and Drug Administration.